MSA Safety
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
MSA Safety Incorporated is a prominent global manufacturer and provider of safety equipment, specializing in the engineering, production, and distribution of solutions designed to safeguard both perso...
Latest News
3 days ago · prnewswire.com
MSA Safety Declares Quarterly DividendPITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- The Board of Directors of MSA Safety Incorporated (NYSE: MSA) today declared a fourth quarter dividend of $0.54 per share on common stock, payable December 10, 2026, to shareholders of record on November 13, 2026. The Board also declared a dividend of $0.5625 per share on preferred stock, payable December 1, 2026, to shareholders of record on November 13, 2026.
3 days ago · globenewswire.com
Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate UpdateHighlights FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA) New U.S. composition of matter patent granted for ATH434, extending protection to 2045 and supporting future development in Parkinson's disease Peer-reviewed publication in Clinical Autonomic Research from the bioMUSE Natural History Study linked skin α-synuclein deposition to autonomic dysfunction in early MSA Phase 3 operational activities underway Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximize long-term shareholder value Cash balance of A$41.3 million at 30 September 2026, inclusive of A$3.98 million Australian R&D Tax Incentive refund and approximately net A$5.5 million raised through the exercise of ATHO listed options MELBOURNE, Australia and SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2026 (Q1 FY27). “This was a quarter of meaningful progress for Alterity,” said David Stamler, M.D.
11 days ago · prnewswire.com
MSA Safety Announces ALTAIR io™ 6 Contract with Major Northeast U.S. Utility ProviderLargest ALTAIR io 6 contract to date underscores growing demand for connected worker safety technology PITTSBURGH, Oct. 22, 2026 /PRNewswire/ -- MSA Safety Inc., (NYSE: MSA), a global leader in advanced safety technology, today announced it is proud to partner with one of the largest utility providers in the northeast United States as the utility invests in connected technologies that support worker safety to better serve their communities. The major U.S. energy utility selected the MSA Safety ALTAIR io™ 6 Multigas Detector to help enhance worker safety and operational efficiency.
13 days ago · prnewswire.com
MSA Safety Schedules Third Quarter 2026 Earnings Conference CallPITTSBURGH, Oct. 20, 2026 /PRNewswire/ -- MSA Safety Incorporated (NYSE: MSA), a global leader in the development of advanced safety products and solutions that protect people and facility infrastructures, today announced that it will host the company's third quarter 2026 earnings conference call on Tuesday, November 3, 2026, at 10:00 a.m. Eastern Time.
13 days ago · zacks.com
MSA Safety (MSA) Earnings Expected to Grow: What to Know Ahead of Q3 ReleaseMSA Safety (MSA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 month ago · zacks.com
MSA Safety (MSA) Upgraded to Buy: Here's What You Should KnowMSA Safety (MSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
1 month ago · gurufocus.com
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDSÂ 2026PR NewswireVALBY,
1 month ago · proactiveinvestors.com
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapyTiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare neurodegenerative disease with no approved disease-modifying therapies. MSA is a rapidly progressive disorder that affects autonomic functions such as blood pressure and bladder control, as well as motor control, leading to severe disability and shortened life expectancy.
1 month ago · prnewswire.com
MSA Safety Launches New G1™ City Edition SCBA, Transforming Firefighter Search and RescueIntegrated Technology Helps to Find Firefighters, New Design Features Reduce Weight, Enhance Comfort PITTSBURGH, Sept. 23, 2026 /PRNewswire/ -- At fire scenes, firefighter safety means more than air supply, it can also mean connectivity, accountability and the ability to quickly locate firefighters in distress.
2 months ago · prnewswire.com
MSA Safety to Showcase Comprehensive Worker Safety Solutions at NSC 2026Highlights include connected gas detection, market-leading head protection and trusted fall protection designed to help improve safety, compliance and productivity INDIANAPOLIS, Sept. 14, 2026 /PRNewswire/ -- Every jobsite faces different hazards, and no single solution fits every worker, application or environment.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MSA